A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population
| Autor: | Ashwaq AlAnzi, Maha Al-Rasheed, Rawan Alshalhoub, Norah O. Abanmy, Dana Bakheet |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty WSB-1 WB repeat and SOCs box-containing endocrine system Deiodinase 1 Population Deiodinase Pharmaceutical Science DIO2 030209 endocrinology & metabolism Disease Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine TSHβ thyroid-stimulating homorne-β T4 tetraiodothyronine education Thyroid cancer UGT1A UDP glucuronosyltransferase family 1 member A Genetic association Pharmacology education.field_of_study T3 triiodothyronine biology business.industry lcsh:RM1-950 DIO (1 2 3) deiodinase (1 2 3) gene D (1 2) deiodinase (1 2) protein Deiodinase 2 thyroxine therapy medicine.disease Differentiated thyroid cancer 030104 developmental biology Endocrinology TH thyroid hormone lcsh:Therapeutics. Pharmacology rs1388378 Cohort biology.protein UDP uridine phosphorylase business FT4 free thyroxin Hormone |
| Zdroj: | Saudi Pharmaceutical Journal, Vol 27, Iss 6, Pp 841-845 (2019) Saudi Pharmaceutical Journal : SPJ |
| ISSN: | 1319-0164 |
| Popis: | Background: Deiodinases comprise a group of selenoproteins that regulate the bioavailability of active thyroid hormones (TH) in a time and tissue specific fashion. They increase the hormonal activity by metabolizing their inactive precursors to active forms or terminate their activity by deactivating active hormones. The role of the deiodinase (DIO) gene polymorphisms in thyroid cancer is not fully understood yet. This study evaluated the potential association of the DIO1 and DIO2 genes with differentiated thyroid cancer and differential thyroxine dose requirement in thyroidectomized patients in a Saudi cohort. Methods: We selected four variants (one DIO1 and three DIO2) for the association studies using Taqman assays in 507 DTC patients undergoing treatment with thyroxin against 560 disease-free individual, all of Saudi Arab origin. Results: None of the studied variants was linked to differentiated thyroid cancer. The rs1388378_G > T was initially linked to thyroxine dose requirement (p = 0.035) when all patients were considered together, but this association was lost when the patients were classified into either near suppressed (0.1 ≤ TSH |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|